We have investigated the role of adenosine diphosphate (ADP) receptors in the adhesion, activation, and aggregation of platelets perfused over immobilized von Willebrand factor (VWF) under high shear stress. Blocking P2Y 1 prevented stable platelet adhesion and aggregation, indicative of a complete inhibition of ␣ IIb ␤ 3 activation, and decreased the duration of transient arrests from 5.9 seconds ؎ 2.8 seconds to 1.2 seconds ؎ 0.8 seconds; in contrast, blocking P2Y 12 inhibited only the formation of larger aggregates. Moreover, blocking P2Y 1 decreased the proportion of platelets showing early intracytoplasmic Ca ؉؉ elevations (␣/␤ peaks) from 20.6% ؎ 1.6% to 14.6% ؎ 1.5% (P < .01), and the corresponding peak ion concentration from 1543 nM ؎ 312 nM to 1037 nM ؎ 322 nM (P < .05); it also abolished the Ca ؉؉ elevations seen in firmly attached platelets (␥ peaks). Blocking P2Y 12 had no effect on these parameters, and did not enhance the effect of inhibiting P2Y 1 . Inhibition of phospholipase C had similar consequences as the blocking of P2Y 1 , whereas inhibition of Src family kinases abolished both type ␣/␤ and ␥ Ca ؉؉ oscillations, although the former effect required a higher inhibitor concentration. Our results demonstrate that, under elevated shear stress conditions, ADP signaling through P2Y 1 may contribute to the initial stages of platelet adhesion and activation mediated by immobilized VWF, and through P2Y 12 to sustained thrombus formation. ( 
Introduction
Platelets adhere and aggregate at sites of vascular injury, contributing to the arrest of bleeding but also to the pathologic occlusion of diseased vessels. 1 At high shear rates, equivalent to those generated by blood flow in arterioles or stenotic arteries, adhesion requires von Willebrand factor (VWF) endogenously present in the subendothelial matrix or absorbed onto injured tissue components exposed to plasma. The membrane glycoprotein (GP) Ib␣, a component of the GP Ib-IX-V complex, 2 can initiate platelet adhesion to the immobilized VWF A1 domain (VWF-A1) while opposing elevated shear forces, but cannot support permanent attachment. Nonetheless, this step is instrumental in the formation of additional bonds that lead to stable platelet adhesion and aggregation mediated by the activated integrin ␣ IIb ␤ 3 and the collagen receptors, GP VI and ␣ 2 ␤ 1 , among others. [3] [4] [5] [6] Recent studies have demonstrated the existence of different Ca ϩϩ signals associated with the engagement of GP Ib-IX-V and ␣ IIb ␤ 3 during platelet adhesion under flow. 7, 8 In particular, the interaction of GP Ib␣ with VWF-A1 leads to sequential elevations in intracytoplasmic Ca ϩϩ concentration ([Ca ϩϩ ] i ) of which the first (␣/␤ peak) may be associated with mechanical stimulation and rapid Ca ϩϩ release from intracellular stores. This signal appears to be coupled to a first stage of ␣ IIb ␤ 3 activation that mediates the shift from transient to a more prolonged adhesion and is regulated by cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) levels. A second stage of ␣ IIb ␤ 3 activation must then be reached for irreversible adhesion and aggregation to occur, and this appears to be associated with a second [Ca ϩϩ ] i elevation (␥ peak) of greater amplitude and duration involving a transmembrane ion flux. 8 The signaling cascade responsible for generating the GP Ib␣ and VWF-dependent Ca ϩϩ peaks remains to be elucidated.
In previous studies it was established that secreted adenosine diphosphate (ADP) is necessary for the shear-induced platelet aggregation initiated by the interaction of soluble VWF with GP Ib␣. 9 ADP binds to different G protein-linked P2 receptors, of which 2 (P2Y 1 and P2Y 12 ) are present on platelets. 10,11 Ligation of P2Y 1 , linked to G q , activates phospholipase C (PLC) and mobilizes Ca ϩϩ from intracellular stores, leading to the activation of protein kinase C and subsequent platelet aggregation. Ligation of P2Y 12 , linked to G i , inhibits adenylyl cyclase, lowers cAMP levels, and potentiates ADP-induced platelet aggregation. 12, 13 The function of both P2Y 1 and P2Y 12 is required for platelet aggregation after adhesion to collagen-bound VWF under flow conditions. 14 With the present studies we have defined the distinct roles that P2Y 1 and P2Y 12 play in the early events that follow the initial platelet interaction with immobilized VWF-A1 under high flow conditions. In particular, we have examined the consequences of specific pharmacologic inhibition of P2 receptors and selected signaling pathways on the occurrence of intracytoplasmic calcium signals related to ␣ IIb ␤ 3 activation and the transition from initial platelet contacts to stable adhesion and subsequent aggregation into thrombi. Our findings demonstrate a differential role of P2Y 1 and P2Y 12 , respectively, in platelet adhesion and aggregation onto immobilized VWF under elevated shear stress, and highlight the distinct contribution of signaling pathways dependent on Src family kinases, PLC, and phosphoinositide 3-kinase (PI 3-K) to these processes.
Materials and methods

Preparation of blood samples
Venous blood from medication-free, healthy volunteers, who gave their informed consent according to the declaration of Helsinki, was collected into a 1:6 final volume of citric acid/citrate/dextrose, pH 4.5, or a specific ␣-thrombin inhibitor, either hirudin (Iketon, Milan, Italy) at the final concentration of 400 U/mL or D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone dihydrochloride (PPACK; Calbiochem, La Jolla, CA) at the final concentration of 50 M. Acid-citrate-dextrose (ACD)-containing blood (50 mL) was centrifuged at 1000g for 50 seconds at 22°C to 25°C, and the supernatant platelet-rich plasma (PRP) was collected. The procedure was repeated twice to obtain approximately 15 mL PRP. The platelets were incubated for 20 minutes at 37°C with the fluorescent calcium probe fluo-3 acetoxymethyl ester-AM (FLUO 3-AM; Molecular Probes, Eugene, OR) at the final concentration of 8 M. Erythrocytes separated from the same blood were washed 3 times in a divalent cation-free HEPES-Tyrode buffer (10 mM Hepes [N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid], 140 mM NaCl, 2.7 mM KCl, 0.4 mM NaH 2 PO 4 , 10 mM NaHCO 3 , and 5 mM dextrose, pH 6.5) and finally resuspended in the same buffer and with the addition of 1.75 mM Probenecid (Sigma, St Louis, MO), used to prevent leakage of FLUO 3-AM from the platelets. 15 An adequate volume of PRP containing 2 ϫ 10 8 to 8 ϫ 10 8 FLUO 3-AM-loaded platelets/mL was mixed with an aliquot of the erythrocyte suspension (50% hematocrit) and apyrase (grade III; 142 ATPase U/mg protein; Sigma) at the final concentration of 5 ATPase U/mL. The mixture was centrifuged at 1000g for 15 minutes, the supernatant was discarded, and the cell pellet was suspended in autologous plasma (prepared from the blood collected in hirudin or PPACK by centrifugation at 1650g for 15 minutes at 22°C to 25°C) or Hepes-Tyrode buffer pH 7.4 and 1.75 mM Probenecid in a proportion such that the hematocrit was 42% to 45%. The labeling procedure did not significantly alter the function of platelets as evidenced by the response to agonists and the expression of surface activation markers. 8
Perfusion experiments
Human VWF was prepared from plasma as previously described. 16 The protein was diluted in phosphate-buffered saline (20 mM Na 2 HPO 4 , 20 mM NaH 2 PO 4 , 2.7 mM KCl, 0.15 M NaCl, pH 7.4) to a final concentration of 100 g/mL, and 100 L of the solution was used to coat glass coverslips for 60 minutes at 22°C to 25°C. These were then washed with the coating buffer and kept in a moist environment until assembled in a modified Hele-Shaw flow chamber. 4, 17 The chamber was positioned in an inverted microscope equipped with epifluorescent illumination (Diaphot-TMD; Nikon Instech, Kanagawa, Japan), an intensified CCD videocamera (C-2400-87; Hamamatsu Photonics, Shizuoka, Japan), and appropriate filters. The total area of an optical field corresponded to approximately 0.007 mm 2 . Blood cells were aspirated through the chamber with a syringe pump (Harvard Apparatus, Boston, MA) at a flow rate calculated to obtain a wall shear rate of 3000 s Ϫ1 at the inlet. When indicated, various substances were added to the blood cell suspension before perfusion. These included prostaglandin (PG) E 1 (which increases the cAMP levels in platelets; Sigma); PP1, PP2, and PP3 (PP1 and PP2 inhibit Src family kinases, and PP3 is a noninhibitory analog control; Calbiochem); apyrase (grade III, 142 ATPase U/mg, or purified to 7641 U/mg; Sigma); wortmannin and LY294002 (which inhibit PI 3-K; both from Sigma); U73122 (which inhibits PLC) and the structurally related inactive analog, U73343 (Calbiochem-Nova Biochem, Bad Soden, Germany); MRS2216 (which inhibits P2Y 1 ; kindly provided by Dr K. A. Jacobson, National Institutes of Health, Bethesda, MD) 18 ; 2 additional P2Y 1 inhibitors (A3P5P and MRS2179, both from Sigma) 12 ; AR-C69931MX (which inhibits P2Y 12 ; from Astra Zeneca Pharmaceutical LP, Wilmington, DE) 19, 20 ; and acetyl salicylic acid (ASA; which inhibits cyclooxygenase-1 and, thus, the generation of thromboxane A 2 ). To prepare a solution of the latter, powdered lysin-acetyl-salicylate (Sanofi-Synthelabo S.p.A., Milano, Italy) was dissolved into a 0.9% NaCl solution at a final concentration of 10 mM (stock solution). Monoclonal immunoglobulins G (IgG), used when indicated, were prepared and characterized as described previously; in particular, the monoclonal antibody LJ-CP8 blocks the binding of ␣ IIb ␤ 3 to both VWF and fibrinogen. 21 Human fibrinogen, used in perfusion experiments, was prepared from human plasma as previously described. 22, 23 Experiments were recorded in real time on videotape at the rate of 25 frames/second, which resulted in a time resolution of 0.08 seconds. Selected video sequences were also digitized in real time using a Matrox-Digisuite board (Matrox Graphics, Dorval, QC, Canada).
Measurement of motion and Ca ؉؉ mobilization in single platelets, and platelet aggregate size
Image analysis was performed either on recorded experiments or in-line using custom-made software (Amplimedical, Casti Imaging Division, Venice, Italy). The program tracks the area of single platelets and determines the position of the corresponding centroid on all the frames collected at a sampling rate of 25 per second, then calculates instant velocity and variations of light intensity measured as the total of all the pixels in a platelet. Thus, information on the measured parameters was obtained every 0.04 seconds. Instantaneous velocity was calculated according to the general equation v ϭ s/t, modified with appropriate algorithms to minimize the effect of variations in centroid position resulting from changes in platelet shape or orientation. 8 Arrest times were calculated from the sum of all the frames in which a platelet had zero velocity, thus was not displaced from its position according to a definition previously published. 3 Stable adhesion was defined as zero velocity for 30 seconds or more. In this case, the surface imprint of a platelet in the first frame of the observation period was overlapping at least partially with the imprints in all subsequent 749 frames. The variations in intensity of the FLUO 3-AM fluorescence were converted into [Ca ϩϩ ] i using the equation [Ca ϩϩ ] i ϭ K d F-F min /F max -F where K d is the dissociation constant of FLUO 3-AM for the interaction with Ca ϩϩ , corresponding to 864 nM at 37°C 15 ; F is the measured fluorescence intensity of a single platelet; F max is the fluorescence intensity of single platelets treated with the Ca ϩϩ ionophore A23187 (10 M; Sigma) in the presence of 2 mM CaCl 2 ; and F min is the fluorescence intensity of an unstimulated single platelet. In agreement with previous findings, 8 the analysis of single platelets translocating on immobilized VWF allowed the identification of 2 characteristic [Ca ϩϩ ] i oscillations associated with specific signaling events. The earlier type ␣/␤ peaks are caused by Ca ϩϩ released from intracellular stores and are associated with the typical platelet translocation on VWF mediated by GP Ib␣; the later and longer lasting type ␥ peaks, which always follow at least one ␣/␤ oscillation, are caused by a transmembrane Ca ϩϩ flux and are associated with stationary platelet adhesion to VWF mediated by the activated integrin ␣ IIb ␤ 3 . 8 The computerized program also measured the size of formed platelet aggregates, expressed as the corresponding cross-sectional area assuming an average platelet diameter of 2.4 m (range, 1.6-4 m). Consequently, the objects observed on the surface were arbitrarily classified as single platelets, 2 m 2 to 13 m 2 ; microaggregates, 14m 2 to 50 m 2 ; small aggregates, 51 m 2 to 200 m 2 ; and large aggregates, more than 200 m 2 . 24 
Results
Involvement of the P2Y 1 ADP receptor and selected signaling pathways in mediating stable platelet adhesion and aggregation onto immobilized VWF exposed to a high shear rate Platelets loaded with FLUO 3-AM and suspended in reconstituted blood at a count of 1 ϫ 10 7 /mL (to analyze single platelet events) or 8 ϫ 10 7 /mL to 16 ϫ 10 7 /mL (to analyze aggregation) were perfused over immobilized VWF at the wall shear rate of 3000 s Ϫ1 . The P2Y 1 antagonist, MRS2216, as well as the PI 3-K inhibitor, wortmannin, completely abolished formation of platelet aggregates, whereas the P2Y 12 antagonist, AR-C69931MX, exerted a partial but significant inhibitory effect only on the formation of larger aggregate, and ASA had no effect ( Figure 1 ). Two additional P2Y 1 receptor antagonists, A3P5P and MRS2179, both used at the final concentration of 250 M, inhibited platelet aggregate formation as effectively as MRS2216 (data not shown). Measurement of the instantaneous velocity of individual platelets translocating on VWF revealed a typical stop-and-go motion with alternating rapid deceleration and acceleration, and permitted to calculate the mean translocation velocity and mean arrest time. The P2Y 1 receptor antagonist, MRS2216, greatly increased the platelet translocation velocity onto VWF and decreased the arrest time at sites of transient adhesion, results similar to those observed with the addition of PGE 1 ( Figure 2 , Table 1 ). The 2 other P2Y 1 inhibitors, A3P5P and MRS2179, caused the same effect as MRS2216 (data not shown). Increased platelet translocation velocity and shortened arrest times were also observed after treating the platelets with the PLC inhibitor, U73122 ( Figure 2 , Table 1 ), or the Src family kinase inhibitors, PP2 (Table 1) or PP1 (used at the same final concentration of 25 M, not shown). In contrast, the P2Y 12 receptor antagonist as well as apyrase and ASA caused no change of these platelet kinetic parameters ( Figure 2 , Table 1 ), nor did PP3, a noninhibitory analog of PP2 and PP1 used as a negative control (not shown). To ensure that maximal effects were detected, in selected experiments we verified that the ADP receptor inhibitors gave consistent results when tested at concentrations 2-to 5-fold in excess of those resulting in the greatest inhibition of platelet adhesion or aggregation (not shown). Apyrase was used at a concentration 10-fold in excess of that required to abolish platelet aggregation induced by 2 M ADP. Complete inhibition of aggregation was observed only when apyrase and ADP were preincubated before addition to the platelets, since the primary response to exogenous ADP could not be prevented without preincubation (not shown). Blocking of PI 3-K function with 2 different inhibitors, wortmannin and LY294002, 25 gave different results depending on the concentration used. LY294002 at the highest concentration tested (25 M) increased the translocation velocity of platelets interacting with immobilized VWF and decreased the arrest time, whereas wortmannin at 100 nM only slightly increased the translocation velocity and had essentially no effect on the arrest time ( Figure 2 , Table 1 ). Higher concentrations of wortmannin, up to 1 M, increased the translocation velocity to 4.98 m/second Ϯ 0.68 m/second and decreased the arrest time to 1.56 seconds Ϯ 0.64 seconds, but under these conditions the inhibitory effect may not be limited to PI 3-K. 
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antagonist had no effect on any of the Ca ϩϩ signals exhibited by the platelets interacting with immobilized VWF, whereas the P2Y 1 antagonist, MRS2216, completely blocked the appearance of type ␥ peaks (Figure 3) .
A quantitative analysis of the percentage of platelets showing intracytoplasmic Ca ϩϩ elevations while interacting with immobilized VWF demonstrated that inhibition of P2Y 1 with MRS2216 caused a relatively modest (ϳ 30%) but statistically significant decrease in ␣/␤ peaks ( Figure 4A ). Similar results were obtained with the other 2 P2Y 1 inhibitors, A3P5P and MRS2179 (data not shown). Essentially the same result was also obtained when platelets were treated with U73122, an inhibitor of PLC ( Figure  4A ), in agreement with the concept that the latter enzyme functions downstream of P2Y 1 ligation. 12 The structurally related but inactive U73122 analog, U73343, used at the same final concentration of 20 M, had no effect on platelet adhesion to VWF and calcium signaling (not shown). Scavenging of released ADP with apyrase had no effect in this regard ( Figure 4A ), possibly reflecting the relatively slow kinetics of this enzyme in relation to the rapid ADP effect on P2Y 1 . Inhibition of P2Y 12 or PI 3-K, or inhibition of thromboxane A 2 synthesis with ASA, also did not influence the number of platelets showing ␣/␤ peaks while interacting with immobilized VWF, but PGE 1 completely abolished these events ( Figure 4A) . Likewise, the Src family kinase inhibitor, PP2, prevented the appearance of ␣/␤ peaks when used at the concentration of 25 M (Table 1 ). In contrast, only the P2Y 12 inhibitor and ASA did not affect the frequency of type ␥ Ca ϩϩ peaks, whereas inhibition of P2Y 1 , PI 3-K, and PLC, as well as scavenging of ADP with apyrase, completely blocked these events, as did treatment with PGE 1 ( Figure 4B ). In fact, the P2Y 12 receptor antagonist caused an increase in the proportion of platelets exhibiting ␥ peaks ( Figure 4B ), possibly because under these conditions a greater amount of ADP was available for binding to P2Y 1 . Inhibition of Src family kinases with PP2 obliterated the appearance of ␥ peaks (Table 1) , and the inhibitor concentration required to achieve this effect was 4-fold lower than that required to abolish ␣/␤ peaks (not shown). To investigate the influence of P2Y 1 and P2Y 12 on the frequency of ␣/␤ peaks in single platelets that translocated on immobilized VWF, we performed experiments in the presence of Results were obtained by using the perfusion conditions described in the legend to Figure 2 with a wall shear rate of 3000 s Ϫ1 . The concentrations of the various agents used are reported in the legends to Figure 1 the anti-␣ IIb ␤ 3 monoclonal antibody LJ-CP8, which completely abolished the appearance of ␥ peaks. There was no change in the ␣/␤ peak frequency in single platelets treated with the P2Y 1 or the P2Y 12 receptor antagonists, and the same was true for platelets treated with the PLC inhibitor, U73122 ( Figure 4C ). The maximal intracytoplasmic Ca ϩϩ concentration corresponding to individual type ␣ oscillations was partially but significantly decreased in platelets treated with the P2Y 1 receptor antagonist, MRS2216 (1037 nM Ϯ 322 nM compared with 1543 nM Ϯ 312 nM of the control; P Ͻ .05). The same was true for platelets treated with the PLC inhibitor, U73122 (902 nM Ϯ 110 nM; P Ͻ .01), whereas no such effect was observed with the P2Y 12 antagonist, the ADP scavenger, apyrase, the PI 3-K inhibitors, wortmannin and LY294002, or ASA ( Figure 5A ). In contrast, only the P2Y 12 antagonist and ASA had no effect on the peak intracytoplasmic Ca ϩϩ concentration during type ␥ oscillations, which were obliterated by all the other inhibitors ( Figure 5B ).
Discussion
We demonstrate here the distinct roles of 2 ADP receptors in the activation of platelets interacting with immobilized VWF in a flow field. Others have used apyrase as a scavenger or receptor antagonists to examine whether ADP contributes to VWF-induced ␣ IIb ␤ 3 activation. In one study, 26 blocking ADP-dependent signaling reduced significantly the number of platelets forming stationary adhesion contacts on VWF at the shear rate of 150 s Ϫ1 but not 600 s Ϫ1 or 1880 s Ϫ1 . This finding prompted the conclusion that signal amplification by ADP is not required for VWF-induced platelet activation under intermediate and high shear stress. In a separate report 8 we identified 2 sequential Ca ϩϩ signals associated with the activation of flowing platelets interacting with immobilized VWF. The earlier ␣/␤ peaks, linked to the engagement of GP Ib␣ by VWF-A1, involved Ca ϩϩ release from intracellular stores and preceded stationary adhesion. Since platelets treated with apyrase showed normal ␣/␤ Ca ϩϩ peaks and attached firmly to immobilized VWF, we concluded that ADP stimulation is not needed for the activation of ␣ IIb ␤ 3 that stabilizes adhesion. In contrast, scavenging ADP abrogated the later ␥ peaks that appeared in firmly adherent platelets, suggesting that signal amplification by released ADP is required for full ␣ IIb ␤ 3 activation compatible with aggregation. 8 The results now obtained with selective antagonists of the 2 platelet ADP receptors modify the concepts reported in the literature, 8,23 demonstrating a previously unrecognized role of P2Y 1 in generating the early signals associated with a first level of ␣ IIb ␤ 3 activation required for stable adhesion to VWF. Such a conclusion rests on the observation that platelets with blocked P2Y 1 exhibited the relatively rapid translocation velocity and short transient arrest times sustained by GP Ib␣ binding to VWF-A1 without ␣ IIb ␤ 3 engagement, as seen with PGE 1 -treated platelets. The apparent contradiction, observed previously 8 and confirmed here, that scavenging ADP with apyrase cannot prevent platelets from achieving ␣ IIb ␤ 3 -mediated stable adhesion may reflect the inability of the enzyme to remove releasedADP completely. In support of this hypothesis, adenosine triphosphate (ATP) can be detected with cell surface-bound firefly luciferase even in the presence of apyrase. 27 Since the ATP/ADP ratio in human platelets is approximately 2, 28 and the nucleotides are thought to undergo secretion with the same kinetics, it is likely that some released ADP may persist locally in quantities sufficient to activate P2Y 1 even in the presence of apyrase. In the latter situation, the reduced agonist concentration may result in a limited activation sufficient to support stable adhesion but not generalized aggregation.
Blocking P2Y 1 function decreased by approximately 30% the proportion of platelets that exhibited type ␣ oscillations while translocating on VWF, and reduced by approximately 500 nM the [Ca ϩϩ ] i of a type ␣ peak. The reduction in activation mirrors the proportion of platelets that show a ␥ peak after an ␣ peak, 8 indicating that signaling from P2Y 1 following GP Ib␣-dependent ADP release may be crucial for the increase of [Ca ϩϩ ] i to the levels needed for ␣ IIb ␤ 3 activation. This hypothesis is supported by the observation that inhibition of PLC ␤ , which acts downstream of P2Y 1 and generates an effector of Ca ϩϩ release from intracellular stores (Figure 6 ), 12, 13 inhibits platelet adhesion to VWF and related Ca ϩϩ oscillations as effectively as the P2Y 1 antagonist. PLC ␥ 2, which is also inhibited by U73122, 29 may contribute to GP Ib-dependent signaling as previously inferred from studies on platelet adhesion to VWF under static conditions. 30 Thus, as also suggested elsewhere, 31 intracytoplasmic Ca ϩϩ levels may be related to the degree of activation of platelets interacting with VWF under high shear stress conditions: less than 200 nM equals resting; 400 nM equals ␤ peak, subactivation; 1000 nM equals ␣ peak induced by GP Ib␣ signaling, leading to ADP release; 1500 nM equals ␣ peakϩP2Y 1 signal, first level of ␣ IIb ␤ 3 activation and stable adhesion; more than 1500 nM equals ␥ peak, full ␣ IIb ␤ 3 activation with platelet aggregation modulated by P2Y 12 function (Figure 6) . A recent report 32 indicated that concurrent blockade of both platelet ADP receptors cannot prevent ␣ IIb ␤ 3 activation on platelets adherent to VWF-A1 under static conditions, suggesting that direct signaling through GP Ib␣ may be sufficient for the functional modulation of this integrin. Our present studies confirm that a Ca ϩϩ signal induced by the engagement of GP Ib␣, albeit reduced in intensity, can be detected in P2Y 1 -blocked platelets, and yet cannot lead to firm adhesion to VWF under high shear stress conditions ( Table 1 ). The contribution of P2Y 1 to GP Ib␣-initiated ␣ IIb ␤ 3 activation, therefore, may have different functional relevance in relation to hemodynamic parameters of the blood circulation. Our studies, in agreement with a previous report using platelets with blocked ADP receptors, 32 also indicate that a Src family kinase-dependent pathway is initially involved in the transduction of the signal originated by VWF-A1 binding to GP Ib␣, as shown by the abrogation of all Ca ϩϩ peaks caused by the Src inhibitors PP1 and PP2. Similar conclusions have been reached by others using different experimental conditions. 33, 34 Because greater concentrations of the inhibitors were required to block ␣/␤ as opposed to ␥ peaks, it appears that one or more Src family kinases may participate in sequential steps of platelet activation linked first to stable adhesion and then to aggregation (Figure 6 ).
In contrast to the early role of P2Y 1 in promoting stable platelet adhesion to immobilized VWF, which is an absolute requirement for subsequent aggregation, we found that P2Y 12 is not involved in generating any of the Ca ϩϩ transients initially associated with platelet activation. In particular, we could not detect any effect of blocking P2Y 12 on the firm adhesion of platelets to VWF, as others have reported. 35 Of note, the translocation velocity of P2Y 12 -blocked platelets in the above mentioned publication 35 was lower than that of control platelets reported here and previously. 3, 36 We suggest that measuring platelet-VWF interactions for 2 seconds, as opposed to the 30 seconds of the present study, may increase the experimental error particularly when translocation is minimal during the observation period ( Figure 6 in Goto et al 35 ). On the other hand, we found that P2Y 12 function is critical for the full development of platelet aggregates on immobilized VWF, in agreement with its reported role in shear-induced platelet aggregation initiated by soluble VWF binding to GP Ib␣ and in thrombus formation on collagen-bound VWF. 14 Others have reported that P2Y 12 is involved in maintaining elevated Ca ϩϩ levels in aggregating platelets, 37 a function that is likely to be important for thrombus growth, as we confirm here, but appears to be distinct from earlier signaling events that initiate aggregation.
The contribution of type I PI 3-K to GP Ib␣ signaling remains controversial. Others reported that stationary platelet adhesion to VWF was impaired by wortmannin and LY294002, 2 distinct PI 3-K inhibitors, used at concentrations (100 nM and 25 M, respectively) proven to block PtdIns(3,4,5)P 3 production. 38 Previously 8 and here we found that wortmannin used at 100 nM has a minimal effect on platelet adhesion to VWF and cannot prevent ␣/␤ Ca ϩϩ peaks, but even at 10 nM blocks ␥ peaks linked to ␣ IIb ␤ 3 activation. In the present study, we found that LY294002 39 dose dependently increases the translocation velocity of flowing platelets interacting with immobilized VWF and shortens their arrest time. Similar effects could be obtained with wortmannin, but only at concentrations at which the specificity for PI 3-K inhibition is not assured. In any case, even LY294002 had no effect on type ␣/␤ Ca ϩϩ peaks, while inhibiting completely ␥ peaks. A previous report demonstrated a marked effect of PI 3-K inhibitors on the Ca ϩϩ transients measured in platelets interacting with immobilized VWF under flow, 38 a finding that can now be ascribed more precisely to inhibition of the more sustained ␥ peaks. It is apparent from our results that PI 3-K is not involved in generating the Ca ϩϩ signals linked to the binding of GP Ib␣ to immobilized VWF-A1, but has a role in the induction of early ␣ Iib ␤ 3 activation. The reason why LY294002 blocks the latter event better than wortmannin remains to be explained. The 2 are structurally and mechanistically distinct inhibitors, [39] [40] [41] and may affect differentially other components of the signaling pathways linked to PI 3-K, as seen in other biologic systems, 42 either coupled to the VWF-GP Ib␣ interaction 43 or to P2Y 1 signaling. In conclusion, our findings identify a number of sequential steps in the signaling cascade initiated by the VWF-GP Ib␣ interaction that may contribute to the participation of platelets in hemostasis and atherothrombosis. This information may help in the selection and evaluation of potential targets for pharmacologic intervention aimed at preventing arterial thrombosis. 30, 32 and cAMP/cGMP levels modulate this and other downstream responses. 8 Subsequent events are shown in the platelet on the right. The released ADP binds to the Gq-coupled P2Y1 receptor, which leads to PLC activation and enhances Ca ϩϩ release from internal stores during ␣/␤ oscillations. At this stage, a first level of localized ␣IIb␤3 activation is reached that supports a more prolonged platelet adhesion mediated by the interaction with the RGD sequence in the VWF C1 domain. Initial PI 3-K activation may enhance this response. Subsequently, further PI 3-K activation and possibly the involvement of Src family kinases contribute to a more generalized ␣IIb␤3 activation that permits soluble ligand binding (exemplified here by fibrinogen and VWF) and supports the formation of platelet-platelet aggregates. This second level of ␣IIb␤3 activation is concurrent with or subsequent to a type ␥ [Ca ϩϩ ]i elevation dependent on a transmembrane ion flux. The second ADP receptor, P2Y12, supports the formation of larger platelet aggregates through mechanisms that occur after the measured Ca ϩϩ oscillations. The thromboxane A2 pathway inhibited by aspirin appears to have a very limited role in the successive stages of platelet adhesion, activation, and aggregation induced by the interaction with immobilized VWF. IP3 indicates inositol-1,4,5-trisphosphate; Src, Src family tyrosine kinases; PLC, phospholipase C; PKC, protein kinase C; PI 3-K, phosphatidylinositol 3-kinase.
